SCHEDULE 13G/A: Investment Funds and Managing Member Report 9.9% Stake in PharmaCyte Biotech

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.9% beneficial ownership stake in PharmaCyte Biotech, Inc., primarily through warrants.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of 774,100 shares of Common Stock in PharmaCyte Biotech, Inc. (the "Issuer").
• This represents 9.9% of the Issuer's outstanding Common Stock.
• The shares are issuable upon the exercise of certain warrants held by the Reporting Persons.
• The issuable shares are subject to either a 4.99% or a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 6,968,134 shares of Common Stock outstanding as of December 9, 2024, as stated in the Issuer's Form 10-Q filed on December 13, 2024, plus the 774,100 shares from warrants.
• Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, a Cayman Islands exempted company, holds the shares, with Ayrton Capital LLC, a Delaware limited liability company, serving as its investment manager.
• Waqas Khatri serves as the managing member of Ayrton Capital LLC and is also a director of Alto Opportunity Master Fund, SPC Segregated Master Portfolio B.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding PharmaCyte Biotech's future operations or financial performance.

Management Comments

• The Reporting Persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing is a routine disclosure of a significant ownership stake by an investment entity and its managing member in a biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by an investment fund and its managing member provides transparency regarding the company's ownership structure and may signal investor interest, although the filing explicitly states the investment is passive and not for control.

Key Dates

Keywords

PharmaCyte Biotech, PYBX, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, beneficial ownership, common stock, warrants, investment, SEC filing